Scarica l'app Stockscreener
1.08
12.20%
-0.15
Precedente Chiudi:
$1.23
Aprire:
$1.225
Volume 24 ore:
19.09M
Relative Volume:
5.17
Capitalizzazione di mercato:
$236.23M
Reddito:
$95,000
Utile/perdita netta:
$-327.27M
Rapporto P/E:
-0.5094
EPS:
-2.12
Flusso di cassa netto:
$-239.25M
1 W Prestazione:
-28.00%
1M Prestazione:
-8.47%
6M Prestazione:
-40.00%
1 anno Prestazione:
-60.58%
Intervallo 1D:
$1.00
$1.225
Intervallo di 1 settimana:
$1.00
$1.5299
Portata 52W:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.08 | 269.04M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - jammulinksnews.com
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - jammulinksnews.com
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - jammulinksnews.com
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - jammulinksnews.com
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - jammulinksnews.com
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - jammulinksnews.com
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - jammulinksnews.com
How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - jammulinksnews.com
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com India
When is Allogene Therapeutics Inc. stock expected to show significant growthLow Risk Alerts With Proven Results - jammulinksnews.com
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News
Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest
Understanding Allogene Therapeutics Inc.’s price movementCommunity Entry Consensus Trade Ideas Shared - metal.it
Allogene Therapeutics Inc. Trading Near Value Zone — Recovery AheadWatchlist for Low Risk High Return Stocks Updated - metal.it
RSI Crosses Above 30 for Allogene Therapeutics Inc. — Reversal in SightLow Volatility Stable Growth Picks Rank High - metal.it
Published on: 2025-07-29 12:47:04 - metal.it
What are the technical indicators suggesting about Allogene Therapeutics Inc.Earnings Report Outlook For 2025 - jammulinksnews.com
CAR-T Cell Therapy Market is projected to grow to US$ 20.4 billion - openPR.com
Allogene Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Drawdown Real Time Trading Tips Shared - metal.it
What is the risk reward ratio of investing in Allogene Therapeutics Inc. stockBest Dividend Forecasts To Watch Now - jammulinksnews.com
Does Allogene Therapeutics Inc. stock perform well during market downturnsPre Market Ideas For Beginners - jammulinksnews.com
How does Allogene Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results today - jammulinksnews.com
What institutional investors are buying Allogene Therapeutics Inc. stockBuild a diversified portfolio for steady growth - jammulinksnews.com
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - ADVFN Brasil
Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment - TipRanks
Is Allogene Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - PrintWeekIndia
Global Allogeneic Cell Therapy Market to grow at 25% CAGR on rising demand and trials by 2030 - PharmiWeb.com
Is Allogene Therapeutics Inc. stock a good hedge against inflationConsistent triple returns - jammulinksnews.com
Allogene Therapeutics Inc. Stock Analysis and ForecastExplosive trading growth - PrintWeekIndia
Multiple Insiders Sold Allogene Therapeutics Shares Presenting Weak Signs For Investors - 富途牛牛
What analysts say about Allogene Therapeutics Inc. stockRapid return acceleration - Autocar Professional
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):